Pure Global
NCT06237335

A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants

A Phase 1, Single-Center Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants
ReCode Therapeutics·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cystic Fibrosis
Drug/Device/Intervention
RCT2100
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
ReCode Therapeutics
Location
Auckland, New Zealand
Timeline & enrollment
Phase
Phase 1
Start date
Feb 01, 2024
End date
Aug 17, 2024
Enrollment
32 participants
Primary outcome

The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

Summary

This is the first-in-human study with RCT2100 and is designed to provide safety and
 tolerability data for future clinical studies.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06237335
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06237335 through Pure Global AI's free database. This Phase 1 trial is sponsored by ReCode Therapeutics and is currently Recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.